- Home
- CTO vs CRGX Comparison
CTO vs CRGX Comparison
Compare CTO & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- CRGX
- Stock Information
- Founded
- CTO 1902
- CRGX 2021
- Country
- CTO United States
- CRGX United States
- Employees
- CTO N/A
- CRGX N/A
- Industry
- CTO Real Estate Investment Trusts
- CRGX
- Sector
- CTO Real Estate
- CRGX
- Exchange
- CTO Nasdaq
- CRGX Nasdaq
- Market Cap
- CTO 589.6M
- CRGX 190.0M
- IPO Year
- CTO N/A
- CRGX 2023
- Fundamental
- Price
- CTO $17.69
- CRGX $4.46
- Analyst Decision
- CTO Strong Buy
- CRGX Hold
- Analyst Count
- CTO 3
- CRGX 7
- Target Price
- CTO $22.33
- CRGX $4.67
- AVG Volume (30 Days)
- CTO 372.4K
- CRGX 502.9K
- Earning Date
- CTO 07-29-2025
- CRGX 08-11-2025
- Dividend Yield
- CTO 8.59%
- CRGX N/A
- EPS Growth
- CTO N/A
- CRGX N/A
- EPS
- CTO N/A
- CRGX N/A
- Revenue
- CTO $132,203,000.00
- CRGX N/A
- Revenue This Year
- CTO $20.11
- CRGX $57.81
- Revenue Next Year
- CTO $8.51
- CRGX N/A
- P/E Ratio
- CTO N/A
- CRGX N/A
- Revenue Growth
- CTO 17.48
- CRGX N/A
- 52 Week Low
- CTO $16.12
- CRGX $3.00
- 52 Week High
- CTO $21.15
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- CTO 45.36
- CRGX 57.89
- Support Level
- CTO $17.10
- CRGX $4.09
- Resistance Level
- CTO $17.71
- CRGX $4.51
- Average True Range (ATR)
- CTO 0.37
- CRGX 0.18
- MACD
- CTO -0.05
- CRGX 0.00
- Stochastic Oscillator
- CTO 53.80
- CRGX 77.18
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.